SRP-9003
SRP-9003-101
Phase 2 gene_therapy terminated
Quick answer
SRP-9003 for Limb-Girdle Muscular Dystrophy, Type 2E is a Phase 2 program (gene_therapy) at Sarepta Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sarepta Therapeutics
- Indication
- Limb-Girdle Muscular Dystrophy, Type 2E
- Phase
- Phase 2
- Modality
- gene_therapy
- Status
- terminated